BHP Billiton Limited vs Smith & Nephew plc — how do they compare? BHP Billiton Limited trades at $91.53 (market cap $229.15B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: BHP Billiton Limited is far larger — about 18.3× Smith & Nephew plc's market cap, and BHP Billiton Limited pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BHP | SNN | |
|---|---|---|
Market Cap | $229.15B | $12.54B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $38.70 |
52-Week Low | $52.14 | $28.73 |
Enterprise Value | $243.35B | $15.57B |
Dividend Yield | 2.95% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.
The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.
No Aura AI signal available yet.
Trailing returns across standard periods
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →